Cite
A blood-brain barrier-penetrant AAV gene therapy improves neurological function in symptomatic mucolipidosis IV mice.
MLA
Sangster, Madison L., et al. “A Blood-Brain Barrier-Penetrant AAV Gene Therapy Improves Neurological Function in Symptomatic Mucolipidosis IV Mice.” Molecular Therapy. Methods & Clinical Development, vol. 32, no. 2, May 2024, p. 101269. EBSCOhost, https://doi.org/10.1016/j.omtm.2024.101269.
APA
Sangster, M. L., Bishop, M. M., Yao, Y., Feitor, J. F., Shahriar, S., Miller, M. E., Chekuri, A. K., Budnik, B., Bei, F., & Grishchuk, Y. (2024). A blood-brain barrier-penetrant AAV gene therapy improves neurological function in symptomatic mucolipidosis IV mice. Molecular Therapy. Methods & Clinical Development, 32(2), 101269. https://doi.org/10.1016/j.omtm.2024.101269
Chicago
Sangster, Madison L, Martha M Bishop, Yizheng Yao, Jessica F Feitor, Sanjid Shahriar, Maxwell E Miller, Anil K Chekuri, Bogdan Budnik, Fengfeng Bei, and Yulia Grishchuk. 2024. “A Blood-Brain Barrier-Penetrant AAV Gene Therapy Improves Neurological Function in Symptomatic Mucolipidosis IV Mice.” Molecular Therapy. Methods & Clinical Development 32 (2): 101269. doi:10.1016/j.omtm.2024.101269.